Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors

Andrew Berchuck, Matthew F. Kohler, Michael P. Hopkins, Peter A. Humphrey, Stanley J. Robboy, Gustavo C. Rodriguez, John T. Soper, Daniel L. Clarke-Pearson, Robert C. Bast

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

Since overexpression of mutant p53 protein is a common feature of invasive epithelial ovarian cancers, we investigated whether overexpression of the p53 tumor suppressor gene product occurs in benign and borderline epithelial ovarian tumors. Immunohistochemical staining for p53 was performed in frozen samples of 17 benign tumors and in 49 borderline tumors (4 frozen, 45 paraffin embedded). Overexpression of p53 was observed in 0/17 (0%) benign ovarian tumors and 2/49 (4%) borderline tumors. Overexpression of p53 in borderline tumors was only seen in advanced stage cases; overexpression was seen in 2/8 (25%) stage III cases, but not in any of 41 stage I/II cases. In conclusion, overexpression of p53 is not a feature of benign epithelial ovarian tumors or early-stage borderline ovarian tumors. Similar to invasive epithelial ovarian cancers, however, a fraction of metastatic borderline tumors also overexpress p53.

Original languageEnglish (US)
Pages (from-to)232-236
Number of pages5
JournalGynecologic oncology
Volume52
Issue number2
DOIs
StatePublished - Feb 1994
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors'. Together they form a unique fingerprint.

Cite this